Unique Challenges With Gene Therapy in Duchenne Muscular Dystrophy


The co-founder, president, and chief executive officer of Solid Biosciences, whose own son has DMD, discussed challenges in developing gene therapies for DMD.

“I would say that my philosophy has always been that our job at Solid is to derisk the approach and derisk [Duchenne muscular dystrophy] and continue to innovate and push the envelope as far as science can go. Six, 7 years ago, treating Duchenne patients with gene therapy was simply crazy. Now, it's obvious and everybody's doing it.”

Solid Biosciences is using advanced gene therapy approaches to try and fill a great unmet need for patients with Duchenne muscular dystrophy (DMD). The mission is personal for the company’s co-founder, president, and chief executive officer, Ilan Ganot: his son has been diagnosed with the disease.

Their lead program, SGT-001, a gene therapy transfer agent, is currently in phase 1/2 clinical trials. It has continued to show safety and efficacy in the first 8 patients dosed, and data from the first 6 patients showed that those who received a high-dose version exhibited 5% to 17.5% of normal microdystrophin expression levels by Western blot and 20% to 70% of positive muscle fibers by immunofluorescence.

GeneTherapyLive spoke with Ganot about the challenges in using gene therapy in DMD, such as the transduction of the therapy to the muscles. He discussed the continual promising data in SGT-001 as well as another program in development, SGT-003, which is focused on identifying and utilizing a more efficient vector for gene therapy.

Morris CA, Clary CM, Redican S, et al. IGNITE-DMD phase I/II study of SGT-001 microdystrophin gene therapy for Duchenne muscular dystrophy. Presented at: 2021 American Society of Gene & Cell Therapy Annual Meeting; May 12-15, 2021. Abstract 263
Related Videos
Xandra Breakefield, PhD, on Trying New Approaches to AAV Therapy for Glioblastoma
Nathan Yozwiak, PhD, on Researching AAV Gene Therapy Delivery to the Brain
Salvador Rico, MD, PhD, on Informing Clinical Trials With Natural History Studies in Dravet
Zheng-Yi Chen, DPhil, on International Collaboration on Clinical Trials
Janice Chen, PhD, the cofounder and chief technology officer of Mammoth Biosciences
Sekar Kethiresan, MD, on Following up VERVE-101 With Next-Generation Editing Therapies
Maria Escolar, MD, the chief medical officer of Forge Biologics
Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies
John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Erika Fullwood Augustine, MD, MS, the associate chief science officer of the Kennedy Krieger Institute
© 2024 MJH Life Sciences

All rights reserved.